Subclinical microvascular changes in ANCA-vasculitides: the role of optical coherence tomography angiography and nailfold capillaroscopy in the detection of disease-related damage.
Anti-neutrophil cytoplasm autoantibodies
Damage
Optical coherence tomography angiography
Retina
Vasculitides
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
10 07 2023
10 07 2023
Historique:
received:
16
02
2023
accepted:
18
06
2023
medline:
12
7
2023
pubmed:
11
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Both cardiovascular and complement-mediated disorders might lead to microvascular damages in anti-neutrophil cytoplasm autoantibodies (ANCA)-associated vasculitides (AAV). We aimed at investigating, for the first time, subclinical microvascular abnormalities with non-invasive techniques in AAV patients by analyzing both retinal and nailfold capillary changes. Retinal plexi were investigated using optical coherence tomography angiography (OCT-A), while nailfold capillary changes by video-capillaroscopy (NVC). Potential correlations between microvessels' abnormalities and disease damage were also explored. An observational study was conducted on consecutive patients who met the inclusion criteria of defined diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA), age ≥ 18 ≤ 75 yrs, and no ophthalmological disorders. Disease activity was assessed by Birmingham Vasculitis Activity Score (BVAS), damage by Vasculitis Damage Index (VDI), and poorer prognosis by the Five Factor Score (FFS). Quantitative analysis of vessel density (VD) was performed by OCT-A in both superficial and deep capillary plexi. Figures and detailed analysis from NVC were performed for all subjects in the study. Included AAV patients (n = 23) were compared with 20 age/sex-matched healthy controls (HC). Retinal VD in superficial whole and parafoveal plexi resulted significantly decreased in AAV compared to HC (P = 0.02 and P = 0.01, respectively). Furthermore, deep whole and parafoveal vessel density was strongly reduced in AAV than HC (P ≤ 0.0001 for both). In AAV patients, significant inverse correlations occurred between VDI and OCTA-VD in both superficial (parafoveal, P = 0.03) and deep plexi (whole, P = 0.003, and parafoveal P = 0.02). Non-specific NVC pattern abnormalities occurred in 82% of AAV patients with a similar prevalence (75%) in HC. In AAV, common abnormalities were edema and tortuosity in a comparable distribution with HC. Correlations between NVC changes and OCT-A abnormalities have not been described. Subclinical microvascular retinal changes occur in patients with AAV and correlate with the disease-related damage. In this context, the OCT-A can represent a useful tool in the early detection of vascular damage. AAV patients present microvascular abnormalities at NVC, whose clinical relevance requires further studies.
Sections du résumé
BACKGROUND
Both cardiovascular and complement-mediated disorders might lead to microvascular damages in anti-neutrophil cytoplasm autoantibodies (ANCA)-associated vasculitides (AAV). We aimed at investigating, for the first time, subclinical microvascular abnormalities with non-invasive techniques in AAV patients by analyzing both retinal and nailfold capillary changes. Retinal plexi were investigated using optical coherence tomography angiography (OCT-A), while nailfold capillary changes by video-capillaroscopy (NVC). Potential correlations between microvessels' abnormalities and disease damage were also explored.
METHODS
An observational study was conducted on consecutive patients who met the inclusion criteria of defined diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA), age ≥ 18 ≤ 75 yrs, and no ophthalmological disorders. Disease activity was assessed by Birmingham Vasculitis Activity Score (BVAS), damage by Vasculitis Damage Index (VDI), and poorer prognosis by the Five Factor Score (FFS). Quantitative analysis of vessel density (VD) was performed by OCT-A in both superficial and deep capillary plexi. Figures and detailed analysis from NVC were performed for all subjects in the study.
RESULTS
Included AAV patients (n = 23) were compared with 20 age/sex-matched healthy controls (HC). Retinal VD in superficial whole and parafoveal plexi resulted significantly decreased in AAV compared to HC (P = 0.02 and P = 0.01, respectively). Furthermore, deep whole and parafoveal vessel density was strongly reduced in AAV than HC (P ≤ 0.0001 for both). In AAV patients, significant inverse correlations occurred between VDI and OCTA-VD in both superficial (parafoveal, P = 0.03) and deep plexi (whole, P = 0.003, and parafoveal P = 0.02). Non-specific NVC pattern abnormalities occurred in 82% of AAV patients with a similar prevalence (75%) in HC. In AAV, common abnormalities were edema and tortuosity in a comparable distribution with HC. Correlations between NVC changes and OCT-A abnormalities have not been described.
CONCLUSION
Subclinical microvascular retinal changes occur in patients with AAV and correlate with the disease-related damage. In this context, the OCT-A can represent a useful tool in the early detection of vascular damage. AAV patients present microvascular abnormalities at NVC, whose clinical relevance requires further studies.
Identifiants
pubmed: 37430363
doi: 10.1186/s13023-023-02782-7
pii: 10.1186/s13023-023-02782-7
pmc: PMC10332066
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
184Informations de copyright
© 2023. The Author(s).
Références
Mod Rheumatol. 2011 Oct;21(5):519-23
pubmed: 21308387
Cent Eur J Immunol. 2020;45(2):218-227
pubmed: 33456335
Autoimmun Rev. 2020 Mar;19(3):102458
pubmed: 31927087
Front Med (Lausanne). 2021 Feb 24;8:627776
pubmed: 33718405
J Rheumatol. 2021 Jan 1;48(1):25-34
pubmed: 32358156
Front Immunol. 2014 Nov 03;5:549
pubmed: 25404930
Turk J Ophthalmol. 2021 Apr 29;51(2):127-130
pubmed: 33951903
Ophthalmology. 1991 May;98(5 Suppl):741-56
pubmed: 2062510
Front Med (Lausanne). 2020 Dec 10;7:583944
pubmed: 33425936
Rom J Ophthalmol. 2020 Jan-Mar;64(1):3-7
pubmed: 32292850
Ann Rheum Dis. 2007 Mar;66(3):283-92
pubmed: 16728460
QJM. 1994 Nov;87(11):671-8
pubmed: 7820541
J Neuroophthalmol. 2005 Mar;25(1):29-32
pubmed: 15756130
Rheumatol Int. 2021 Dec;41(12):2069-2089
pubmed: 34635927
Retina. 2015 Nov;35(11):2188-95
pubmed: 26469536
Orphanet J Rare Dis. 2020 Jan 17;15(1):20
pubmed: 31952522
Rheumatology (Oxford). 2023 Feb 1;62(2):747-757
pubmed: 35816001
Medicine (Baltimore). 2011 Jan;90(1):19-27
pubmed: 21200183
Arthritis Rheum. 1994 Feb;37(2):187-92
pubmed: 8129773
Microvasc Res. 2021 Jul;136:104173
pubmed: 33895230
Medicine (Baltimore). 2020 Aug 28;99(35):e21934
pubmed: 32871935
Acta Ophthalmol. 2022 May;100(3):e798-e806
pubmed: 34250739
Ophthalmol Retina. 2022 Jan;6(1):43-48
pubmed: 33901715
J Autoimmun. 2014 Feb-Mar;48-49:90-3
pubmed: 24461388
Rheumatology (Oxford). 2021 Dec 1;60(12):5827-5832
pubmed: 33715001
Community Eye Health. 2007 Dec;20(64):74-5
pubmed: 18330450
Eur J Ophthalmol. 2009 Mar-Apr;19(2):314-7
pubmed: 19253257
Clin Med (Lond). 2017 Feb;17(1):60-64
pubmed: 28148583
Rom J Ophthalmol. 2021 Jan-Mar;65(1):93-97
pubmed: 33817443
Lupus. 2022 Dec;31(14):1800-1807
pubmed: 36239237
Case Rep Ophthalmol. 2021 Apr 6;12(1):98-104
pubmed: 33976664
Int J Mol Sci. 2020 Oct 03;21(19):
pubmed: 33023023
J Clin Med. 2020 Nov 30;9(12):
pubmed: 33265997
Ophthalmol Glaucoma. 2023 May-Jun;6(3):291-299
pubmed: 36307064
J Ophthalmic Inflamm Infect. 2011 Jun;1(2):71-5
pubmed: 21484179
BMJ Case Rep. 2021 Oct 27;14(10):
pubmed: 34706910
Lupus. 2022 Apr;31(5):541-554
pubmed: 35282713
Ann Rheum Dis. 2020 Feb;79(2):e18
pubmed: 30573654
Arthritis Rheum. 1997 Feb;40(2):371-80
pubmed: 9041949
Arthritis Rheum. 2005 Sep;52(9):2926-35
pubmed: 16142760
Am J Ophthalmol. 2002 Jan;133(1):151-2
pubmed: 11755858
J Clin Med. 2021 Nov 19;10(22):
pubmed: 34830697
Eur J Ophthalmol. 2003 Oct;13(8):722-5
pubmed: 14620179
Int Arch Allergy Immunol. 2018;177(1):45-56
pubmed: 29902805
Rheum Dis Clin North Am. 2010 Aug;36(3):573-86
pubmed: 20688251
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Int Ophthalmol. 2007 Dec;27(6):369-71
pubmed: 17522782
Br J Ophthalmol. 2006 Nov;90(11):1435-6
pubmed: 17057178
Cureus. 2022 Feb 25;14(2):e22612
pubmed: 35371706
Am J Ophthalmol Case Rep. 2020 Apr 08;18:100683
pubmed: 32309675
Front Med (Lausanne). 2022 Mar 18;9:786708
pubmed: 35372401
Clin Ophthalmol. 2012;6:1225-8
pubmed: 22927731
J Clin Neuroophthalmol. 1985 Dec;5(4):229-37
pubmed: 2934426